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each. Principal components analysis (PCA) was then applied to
the data to identify major types of expenditure trends across all
the different therapeutic classes. RESULTS: In total, across all
drugs in the 64 therapeutic classes, Medicaid spending increased
from $4.6 billion with 231 million prescriptions in 1991 to $22.5
billion with 350 million prescriptions in 2004, representing total
Medicaid spending on outpatient drugs during the time period.
PCA revealed three principal components that accounted for 90
percent of total variation in Medicaid drug expenditure patterns.
The ﬁrst principal component (PC1), explaining 66 percent of the
variation, is an exponential-like upward trend; PC2, explaining
17% of the variation, represents an increasing-then-decreasing
expenditure pattern; and PC3, explaining 7% of the variation,
represents an up-and-down cyclical expenditure pattern. Thera-
peutic classes exhibiting high correlation (r > 0.9) with PC1
include corticoid steroids, anti-neoplastics, anti-seizure agents,
bone density regulators, anti-inﬂammatory agents, antiretroviral
agents, antipsychotics, antidepressants, oral diabetic agents, and
gastrointestinal agents. When PCA was applied to drug utiliza-
tion trends, the same principal components were discovered and
accounted for 92% of total variation in drug utilization patterns.
CONCLUSION: Most drug therapeutic classes exhibited
exponential-like upward expenditure trends, clearly contributing
to the overall rising expenditure burden for Medicaid.
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OBJECTIVE: To describe and characterize a group of private
insurance members taking multiple medications over a one-year
period. METHODS: Persons were selected for this polyphar-
macy analysis if they had at least ﬁve unique maintenance pre-
scriptions in their pharmacy claims records for the period of
January-March 2005, based on a customized list of chronic
medications. The full set of pharmacy and medical claims for
these members were evaluated for a 12-month period, October
2004 to September 2005. Standard descriptive statistics were
calculated to characterize the population. Logistic regression
models were used to assess the association of pharmacy claims
and “safety events” (i.e., emergency room visits (ER) and hospi-
talizations (H)). RESULTS: The ﬁnal analytic sample, having
both pharmacy and medical coverage for the period, consisted of
N = 14,890 members 19 years of age (66% female), from four
U.S. states. There were over 93,000 unique pharmacy claims
with a monthly average of 6.3 per member. Males (M) and
females (F) had similar averages (M = 6.2; F = 6.3), yet males
were more likely to have ER (12.1%M vs. 10.8%F, p = 0.022)
and H (8.3%M vs. 6.3%F, p < 0.0001). Unadjusted logistic
regressions estimated the effect of medication claims on ER and
H as OR = 1.14, p < 0.0001 and OR = 1.18, p < 0.0001, respec-
tively. This implies 14% and 18% higher odds of ER or H,
respectively, for every unit increase in monthly medications.
Adjusting for age and gender does not substantially affect these
results. CONCLUSION: Evaluating serious medical events in
sub-populations taking multiple prescription medications pro-
vides important information for health insurers trying to reduce
ER and hospitalizations. In a privately insured polypharmacy
sub-population, there was a strong association with these safety
events and increased average monthly pharmacy claims. Private
insurers should consider establishing managed care programs to
evaluate and improve the overall safety of their members taking
higher numbers of monthly medications.
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OBJECTIVE: The National Health Insurance (NHI) system in
Taiwan is characterized by 1) free choice of physicians and health
care facilities without formal referral; 2) generous drug beneﬁts;
and 3) low co-payments. The NHI beneﬁciaries thus exhibit
features of frequent attendances, frequent changes of physicians,
and a higher number of drug items in a prescription. It is inter-
esting to know how likely a doctor shopper is to be a patient of
polypharmacy. METHODS: The data sources came from the
historical claims datasets of 200,000-person cohort in 2005,
offered by the National Health Insurance Research Database in
Taiwan. The analysis was limited to the ambulatory records with
conditions of chronic diseases, represented by visits with more
than seven days of drug supply. For those people with at least one
visit for chronic diseases, the degree of correlation between the
total number of consulted facilities and the total number of
distinct prescribed drug items in all visits for chronic diseases in
2005 would be determined. RESULTS: Of the study cohort
56,956 people (30,070 females and 26,886 males; mean age
49.9  19.9 [SD] years) had at least one visit for chronic diseases
in 2005. On average, one of these people had paid 6.8  7.0
(max. 98) visits, consulted 1.5  0.9 (max. 32) facilities, and
received 7.3  7.3 (max. 93) distinct drug items for chronic
diseases in a year. The total number of consulted facilities for
chronic diseases in a year was strongly correlated with the total
number of distinct prescribed drug items in all visits for chronic
diseases in a year (Spearman’s rho 0.548, p < 0.001 [2-tailed]).
CONCLUSION: More visits for chronic diseases at different
facilities were related to more drugs prescribed. Besides the
patients’ reasons, the causes inherent in the health care system
deserve investigations.
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OBJECTIVE: Dosing and therapeutic range of digoxin has
recently changed based on results from clinical trials. We exam-
ined the epidemiology, mortality and length of stay (LOS) of
patients with serum digoxin level results during hospitalization.
METHODS: We retrospectively analyzed 4765 cases with serum
digoxin levels from 2 institutions that electronically provided
laboratory data from 2004–2006. Cases were stratiﬁed into the
groups based on maximum serum digoxin level; <1.0, 1.0–2.0,
2.1–2.4, and >2.4. The actual to predicted hospital mortality and
length of stay was compared across each strata with predicted
mortality and LOS determined by previously described admis-
sion based clinical models. RESULTS: Approximately 3 in 5
cases (57.8%) had a serum digoxin level higher than the recom-
mended range of <1.0. The crude mortality for cases with
digoxin levels <1.0 was 4.1% and 9.1% for those with digoxin
levels  1.0. After adjustment for severity of illness on admission
cases with a digoxin level  1.0 had a signiﬁcantly higher actual
to predicted mortality ratio (1.3 [CI = 1.1–1.4]) than cases <1.0
(0.8 [0.7–1.0]). While crude LOS was higher for serum digoxin
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levels  1.0 (7.2  7.7 days vs. 5.5  5.6 days) after risk adjust-
ment the actual to predicted LOS ratio was not signiﬁcantly
different from 1. CONCLUSION: The majority of cases have
serum digoxin levels that are above the currently recommended
range and cases with serum digoxin levels  1.0 have a higher
mortality. Cases with serum digoxin levels  1.0 did not have
higher risk-adjusted LOS. Digoxin dosing during hospitalization
requires careful monitoring and has the potential of improving
safety and related outcomes.
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OBJECTIVE: The various off-label uses of intravenous immune
globulin (IVIG), used for the treatment of immunodeﬁciency
disorders, far exceeds its labeled indications. This study repre-
sents an effort to identify these uses. METHODS: Clinical studies
concerning the off-label uses of IVIG preparations were identiﬁed
by searching the PUBMED (MEDLINE+) database from January
1, 1998 to January 1, 2006. The search was limited to clinical
trials, meta-analyses, randomized controlled trials, and case
reports in English. RESULTS: A review of 138 clinical trial
abstracts identiﬁed 10 trials examining 2 labeled uses (635
patients) and 128 trials examining 61 different off-label uses
(6781 patients). The top off-label indications included multiple
sclerosis, graft versus host disease in transplant patients, preven-
tion of antiphospholipid syndrome in miscarriage, and Guillan-
Barre syndrome. The studies appear to support many of the
acceptable off-label uses cited by various guideline groups. A
total of 276 case reports were identiﬁed, with 268 reports rep-
resenting 156 different off-label uses (362 patients). Patient out-
comes from published abstracts were positive for 267 patients
(74%). Seven meta-analyses were identiﬁed, evaluating recurrent
miscarriage, in vitro fertilization failure, infection in preterm
infants, multiple sclerosis, immune thrombocytopenic purpura,
and pemphigoid. With the exception of recurrent miscarriage and
infection in preterm infants, the off-label use of IVIG for these
indications was found to have positive outcomes. CONCLU-
SION: Over 150 off-label uses were identiﬁed from reviewing
clinical trials and case reports. An examination of IVIG guide-
lines by specialty society, payer, and other review organizations
shows that the biomedical evidence supporting off-label uses is
being interpreted in different ways. Health care institutions are
strongly urged to approve and closely monitor speciﬁc uses of
IVIG to reserve dwindling supplies for the “best evidence” uses.
Clinicians should be aware of the limits of knowledge in many
off-label uses and exercise restraint in prescribing for unproven
indications.
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OBJECTIVE: Current national patient safety goals call to
“Reduce the likelihood of patient harm associated with the use
of anticoagulation therapy”. We examined the epidemiology,
length of stay and occurrence of bleeding in non-surgical
patients treated with heparin infusions during hospitalization.
METHODS: We retrospectively analyzed 668 non-surgical cases
that were treated with heparin for at least 24 hours during
hospitalization from 2 institutions that electronically provided
laboratory and pharmacy data from 2005–2006. Cases were
categorized into the following groups based on serum APTT
results; subtherapeutic (<51), therapeutic (51–75), above thera-
peutic (76–99) and supratherapeutic (100). The number of
cases meeting each APPT category was compared at approxi-
mately 6 and 24 hours post heparin treatment. The actual to
predicted hospital length of stay was compared for each APTT
category with predicted LOS determined using previously
described admission based clinical models. Bleeding was assessed
by the presence of diagnostic codes. RESULTS: Those with
APTT measured, the percent of cases at 6 and 24 hours were;
20.7 vs. 20.3 for subtherapeutic, 23.4 vs. 31.6 for therapeutic,
16.2 vs. 19.0 for above therapeutic, and 30.4 vs. 18.6 for supra-
therapeutic. There was a 1.8 day excess LOS in the subthera-
peutic group at 24 hours (p < 0.05). Unadjusted bleeding rates
were 21.6% for subtherapeutic, 17.5% in therapeutic, 13.4% in
above therapeutic and 12.1% in supratherapeutic cases at 24
hours. CONCLUSION: One in 5 cases treated with heparin had
a subtherapeutic APTT at 24 hours and these cases had a sig-
niﬁcantly longer LOS. Clinicians responsible for assuring anti-
coagulation safety should incorporate monitoring strategies for
subtherapeutic APTT results as diligently as those for suprath-
erapeutic results.
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OBJECTIVE: To evaluate equity concerns in routine and pre-
ventive health care utilization. METHODS: Data from the
MEPS’s Household Component (2004), a nationally representa-
tive survey of the U.S. civilian noninstitutionalized population,
was used. Equity was deﬁned on the principle of equal treatment
for equal need. Need variables controlled in the model were
perceived health status, presence of illness, comorbidities, activi-
ties and instrumental activities of daily living limitations. Non-
need variables assessed for presence of horizontal equity were
age, gender, race, ethnicity, income, and education. Need vari-
ables were studied to conﬁrm presence of vertical equity, which
was deﬁned as different levels of need variables consuming
appropriate different levels of health care. Equity in routine
health care utilization namely-expenditures on Emergency room
(ER), Inpatient hospitalization (IPH), Outpatient care (OPT),
Ofﬁce-based care (OFB), Dental care (DENTAL), and Prescrip-
tion drugs (RX) were analyzed by GLM with log-link and
Gamma/Poisson families. Binary measures of dental check-up,
cholesterol check-up, blood-pressure check-up, and ﬂu-shots, as
indicators of preventive health care utilization, were analyzed by
logistic and skewed-logistic models. RESULTS: Horizontal ineq-
uity was observed by age, gender, and income in all routine care
variables except ER. Inequity by education was observed in OFB,
DENTAL, and RX. Race related inequity was observed in OFB,
IPH, DENTAL, and RX. Inequity by ethnicity was observed in
utilization of all routine care variables. Necessary condition for
vertical equity was not satisﬁed only in ER and DENTAL utili-
zation. Horizontal inequity was observed in all four preventive
care variables by age, gender, ethnicity, income, and education.
Horizontal inequity by race was observed in cholesterol check-
up, blood pressure check-up, and receipt of ﬂu shots. Evidence of
vertical equity was not observed in preventive care utilization.
CONCLUSION: Horizontal inequity in age, gender, race, ethnic-
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